DSM establishes Biomedical Scientific Advisory Board
The first appointed members include Professor Tony Mikos (Rice University, Houston, USA) who will head up the Biomedical Scientific Advisory Board. He is an expert in the synthesis, processing and application development of new biomaterials and has (co)authored over 330 publications. Furthermore Dr. Ivo Buschmann (Charité, University of Medicine, Berlin and Freiburg University, Germany), and Mr. Patrick Cahalan, BSc (Ension Inc., Pittsburgh, USA) have been appointed. Dr. Buschmann is an Assistant Professor and clinical cardiologist and an expert in cardiovascular research. He heads an international research consortium called Art.Net. which focuses on experimental and clinical research in the field of vascular biology and arteriogenesis (collateral artery growth). Mr. Patrick Cahalan is a medical device industry veteran. He has over three decades of R&D experience, particularly in medical coatings, and holds more than 40 granted and pending patents.
Together with the other members, to be appointed in due course, these experts will provide advice to DSM Biomedical on its research and development strategy and program. The advice will include an assessment of R&D programs and projects vis-à-vis scientific and technological quality, validity of hypotheses, and clinical relevance.
Steve Hartig, Vice President DSM Biomedical: "I am convinced that early validation by external thought leaders of our ideas and inventions on scientific merit and relevance will considerably increase the success rate of our biomedical innovations. We are honored that such leading experts as Tony Mikos, Patrick Cahalan and Ivo Buschmann have committed themselves to our Board ."
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.